Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHV NASDAQ:AGEN NASDAQ:CBIO NASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$5.36-3.4%$4.74$2.00▼$6.16$569.76M2.271.31 million shs1.66 million shsAGENAgenus$2.96-0.7%$3.65$2.71▼$7.34$124.09M1.57579,881 shs723,407 shsCBIOCrescent Biopharma$18.21+1.4%$19.91$8.72▼$27.41$494.64M1.16230,424 shs382,005 shsXOMAXOMA Royalty$41.72-0.1%$40.73$22.29▼$42.81$523.96M0.88100,632 shs80,470 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences-0.89%-0.89%+4.91%+37.38%+79.03%AGENAgenus-8.31%-4.18%-16.76%-20.74%-42.02%CBIOCrescent Biopharma-1.32%-0.28%-10.12%+73.43%-97.66%XOMAXOMA Royalty-0.41%-0.41%+0.07%+52.76%+72.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$5.36-3.4%$4.74$2.00▼$6.16$569.76M2.271.31 million shs1.66 million shsAGENAgenus$2.96-0.7%$3.65$2.71▼$7.34$124.09M1.57579,881 shs723,407 shsCBIOCrescent Biopharma$18.21+1.4%$19.91$8.72▼$27.41$494.64M1.16230,424 shs382,005 shsXOMAXOMA Royalty$41.72-0.1%$40.73$22.29▼$42.81$523.96M0.88100,632 shs80,470 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences-0.89%-0.89%+4.91%+37.38%+79.03%AGENAgenus-8.31%-4.18%-16.76%-20.74%-42.02%CBIOCrescent Biopharma-1.32%-0.28%-10.12%+73.43%-97.66%XOMAXOMA Royalty-0.41%-0.41%+0.07%+52.76%+72.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHVAchieve Life Sciences 3.00Buy$14.67173.63% UpsideAGENAgenus 2.00Hold$23.00677.03% UpsideCBIOCrescent Biopharma 3.11Buy$28.0053.76% UpsideXOMAXOMA Royalty 2.14Hold$53.7528.84% UpsideCurrent Analyst Ratings BreakdownLatest AGEN, XOMA, ACHV, and CBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026XOMAXOMA Royalty Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/22/2026ACHVAchieve Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026XOMAXOMA Royalty BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/13/2026CBIOCrescent Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (D-)5/13/2026XOMAXOMA Royalty Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/11/2026AGENAgenus Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2026ACHVAchieve Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/30/2026XOMAXOMA Royalty HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$39.004/29/2026CBIOCrescent Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/27/2026XOMAXOMA Royalty Lucid Cap MktsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/24/2026ACHVAchieve Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHVAchieve Life SciencesN/AN/AN/AN/A$0.40 per shareN/AAGENAgenus$114.20M1.08N/AN/A($8.17) per share-0.36CBIOCrescent Biopharma$10.84M46.30N/AN/A$14.32 per share1.27XOMAXOMA Royalty$52.15M10.03$0.57 per share73.28$6.77 per share6.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHVAchieve Life Sciences-$54.65M-$1.12N/AN/AN/AN/A-193.49%-111.88%8/6/2026 (Estimated)AGENAgenus$120K$1.591.86N/AN/A50.49%-31.66%42.71%8/10/2026 (Estimated)CBIOCrescent Biopharma-$153.94M-$10.91N/AN/AN/AN/A-103.44%-88.19%7/30/2026 (Estimated)XOMAXOMA Royalty$31.71M$1.5726.57N/AN/A53.46%12.56%4.11%7/30/2026 (Estimated)Latest AGEN, XOMA, ACHV, and CBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ACHVAchieve Life Sciences-$0.30-$0.19+$0.11-$0.19N/AN/A5/12/2026Q1 2026XOMAXOMA Royalty$0.19$0.17-$0.02$0.17$13.91 million$12.32 million5/11/2026Q1 2026AGENAgenus$2.10$1.02-$1.08$1.02$129.50 million$33.74 million4/29/2026Q1 2026CBIOCrescent Biopharma-$0.85-$0.70+$0.15-$0.70$0.36 million$1.04 million3/24/2026Q4 2025ACHVAchieve Life Sciences-$0.27-$0.28-$0.01-$0.28N/AN/A3/18/2026Q4 2025XOMAXOMA Royalty-$0.04$0.12+$0.16$0.26$11.13 million$13.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACHVAchieve Life SciencesN/AN/AN/AN/AN/AAGENAgenusN/AN/AN/AN/AN/ACBIOCrescent BiopharmaN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHVAchieve Life Sciences0.872.622.62AGENAgenusN/A0.380.38CBIOCrescent BiopharmaN/A13.7813.78XOMAXOMA Royalty0.963.593.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHVAchieve Life Sciences33.52%AGENAgenus61.46%CBIOCrescent Biopharma75.19%XOMAXOMA Royalty95.92%Insider OwnershipCompanyInsider OwnershipACHVAchieve Life Sciences1.80%AGENAgenus6.50%CBIOCrescent Biopharma4.00%XOMAXOMA Royalty8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHVAchieve Life Sciences20102.66 million100.81 millionOptionableAGENAgenus44041.64 million38.94 millionOptionableCBIOCrescent Biopharma5027.56 million26.46 millionNo DataXOMAXOMA Royalty1012.54 million11.43 millionOptionableAGEN, XOMA, ACHV, and CBIO HeadlinesRecent News About These CompaniesXOMA Highlights Royalty Aggregation Strategy in Updated PresentationJune 16 at 7:34 PM | theglobeandmail.comXOMA Corp - 8.375% DP PFD B declares $0.5234 dividendJune 13, 2026 | seekingalpha.comXOMA Details Merger Timeline and Preferred Share RedemptionJune 12, 2026 | tipranks.comXOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record DateJune 12, 2026 | globenewswire.comXOMA Royalty (NASDAQ:XOMA) Shares Pass Above 200-Day Moving Average - Here's What HappenedJune 12, 2026 | americanbankingnews.comXOMA Royalty Sets July Vote on $39-per-Share Ligand Takeover and ReorganizationJune 10, 2026 | tipranks.comXOMA (XOMA) Q4 2025 Earnings Call TranscriptJune 2, 2026 | finance.yahoo.comSaying Goodbye To The XOMA Royalty PFDsMay 25, 2026 | seekingalpha.comXOMA Royalty Advances Merger Plans and Governance ChangesMay 22, 2026 | tipranks.comLigand Pharma Advances XOMA Royalty Acquisition with AmendmentMay 18, 2026 | tipranks.comXOMA Royalty amends merger agreement with Ligand PharmaceuticalsMay 18, 2026 | tipranks.comA Look At Ligand Pharmaceuticals (LGND) Valuation After Earnings Miss XOMA Deal And Viking TR-Beta TerminationMay 12, 2026 | finance.yahoo.comXOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the ...April 28, 2026 | bakersfield.comBXOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMAApril 28, 2026 | tmcnet.comXOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?April 28, 2026 | zacks.comRoyalty powerhouse: Ligand and Xoma unite in $739 million dealApril 28, 2026 | msn.com$XOMA stock is up 9% today. Here's what we see in our data.April 27, 2026 | quiverquant.comQALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty CorporationApril 27, 2026 | prnewswire.comLigand Bets On Royalty Growth With XOMA Buyout Worth Over $700 MillionApril 27, 2026 | benzinga.comXOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On MondayApril 27, 2026 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMicrosoft Just Gave Investors 3 Dates They Can't Afford to IgnoreBy Chris Markoch | June 11, 2026Apple’s Agentic AI Plans Could Be Its Biggest Growth Story YetBy Sam Quirke | May 29, 2026AI Can’t Reach the Real World Without These 3 StocksBy Thomas Hughes | May 27, 2026Salesforce Stock Finds Support as AI Momentum BuildsBy Thomas Hughes | May 29, 2026The $132 Billion Infrastructure Pivot You Might Have MissedBy Jeffrey Neal Johnson | May 19, 2026AGEN, XOMA, ACHV, and CBIO Company DescriptionsAchieve Life Sciences NASDAQ:ACHV$5.36 -0.19 (-3.42%) Closing price 04:00 PM EasternExtended Trading$5.44 +0.08 (+1.57%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.Agenus NASDAQ:AGEN$2.96 -0.02 (-0.67%) Closing price 04:00 PM EasternExtended Trading$2.98 +0.02 (+0.84%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Crescent Biopharma NASDAQ:CBIO$18.21 +0.26 (+1.45%) Closing price 04:00 PM EasternExtended Trading$18.00 -0.21 (-1.13%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.XOMA Royalty NASDAQ:XOMA$41.72 -0.06 (-0.14%) Closing price 04:00 PM EasternExtended Trading$41.74 +0.02 (+0.06%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Insider Sales Look Big, But Should Investors Worry? Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves Meta and Cloud Computing: Real Potential, or a Shot in the Dark? Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
